# US 2025/0221982 A1 · Compositions and methods for local delivery of pharmaceutical agents to treat cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0221982 A1
- Document ID: US20250221982A1
- Status: Published application
- Kind: A1
- Application number: 18/984,962
- Filed: 2024-12-17
- Published: 2025-07-10
- Earliest claimed: 2018-07-05
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Shadmehr Demehri
- Web page: https://patentgrep.com/patent/US20250221982A1

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61P 17/00: Drugs for dermatological disorders
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 35/763: Herpes virus
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions comprising a T cell/thymic stromal lymphopoietin (TSLP) activating agent and an innate immunity activating agent, an methods of use thereof to treat cancer, e.g., cutaneous malignancies.

## Claims

### Claim 1

A method for treating a proliferative disorder in the skin of a subject in need thereof, said method comprising administering a therapeutically effective amount of (i) an agent that activates T cells through TSLP induction and (ii) an innate immune cell activating agent, preferably directly to a site of proliferation in the skin of the subject, thereby treating the proliferative disorder in the skin of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the proliferative disorder in the skin is a non-keratinocyte cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the non-keratinocyte cancer is melanoma, extramammary Paget's disease or a breast cancer metastasis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the site of proliferation in the skin is a tumor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the site of proliferation in the skin comprises a metastasis within the chest wall of the subject.

### Claim 6 (depends on 2)

The method of claim 2, wherein the non-keratinocyte carcinoma is not a Squamous Cell Carcinoma (“SCC”), Basal Cell Carcinoma (“BCC”), or a keratinocyte cancer.

### Claim 7 (depends on 1)

The method of claim 1, which does not include administering a cytotoxic agent.

### Claim 8 (depends on 1)

The method of claim 1, wherein the agent that activates T cells through TSLP induction is calcipotriene or retinoic acid.

### Claim 9 (depends on 1)

The method of claim 1, wherein the innate immune cell activating agent is a TLR agonist, STING agonist, or oncolytic virus.

### Claim 10 (depends on 9)

The method of claim 9, wherein the TLR agonist is imiquimod, resiquimod, 852A, motolimod (VTX-2337); CpG-ODN; or ODN2395.

### Claim 11 (depends on 9)

The method of claim 9, wherein the STING agonist is DMXAA, MK-1454 or ADU-S100.

### Claim 12 (depends on 9)

The method of claim 9, wherein the oncolytic virus is Talimogene Laherparepvec (T-Vec).

### Claim 13 (depends on 1)

The method of claim 1, wherein a composition comprising an agent that activates T cells through TSLP induction and a composition comprising an innate immune cell activating agent are administered concomitantly or sequentially.

### Claim 14 (depends on 1)

The method of claim 1, wherein a single composition comprising an agent that activates T cells through TSLP induction and an innate immune cell activating agent is administered.

### Claim 15 (depends on 1)

The method of claim 1, wherein one or both of the agent that activates T cells through TSLP induction and the innate immune cell activating agent is topically administered.

### Claim at position 16

-29. (canceled)
